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Background: Montelukast is a leukotriene receptor antagonist for treatment of asthma, gliclazide is an oral
hypoglycemic antidiabetic agent, and nifedipine is a calcium channel blocker used for treatment of angina pectoris
and hypertension. These drugs may be prescribed to patients suffering from these chronic diseases. A survey of the
literature reveals that there is no reported method for the simultaneous determination of montelukast, gliclazide,
and nifedipine in pharmaceutical preparations or biological fluids.
Results: A simple, sensitive, and rapid method for the simultaneous quantification of montelukast, gliclazide, and
nifedipine in human plasma was developed and validated. Montelukast, gliclazide, and nifedipine were resolved
using rapid resolution LC/MS/MS Agilent system and SB-C18 (50 × 4.6 mm) 1.8 μm particle size column. The mobile
phase consisted of acetonitrile: 0.1% formic acid (84:16). The three drugs were simultaneously extracted from plasma
by protein precipitation with acetonitrile using zaferolukast as an internal standard. The method was validated
according to FDA guidelines with good reproducibility and linearity of 0.999 and the limits of quantification were
0.11, 0.04, and 0.07 ng/mL for montelukast, gliclazide, and nifedipine, respectively. The accuracies of the three QCs
for the three drugs were 99.48% (montelukast), 106.53% (gliclazide), and 108.03% (nifedipine) in human plasma. The
validated method was applied to a pharmacokinetic study in human volunteers after oral administration of the
three drugs. The applied LC/MS/MS method was shown to be sufficiently sensitive and suitable for pharmacokinetic
studies.
Conclusion: The LC/MS/MS method was validated and successfully applied for the determination of montelukast,
gliclazide, and nifedipine concentrations in human plasma.Background
Montelukast, gliclazide, and nifedipine are drugs used
for the management of chronic asthma and as prophy-
lactic agents for exercise-induced asthma, treatment of
non-insulin-dependent diabetes mellitus, and treatment
of angina pectoris and hypertension, respectively.
This study aimed to determine serum concentrations
of these three drugs, which are often jointly prescribed* Correspondence: ezzeldin24@hotmail.com
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article, unless otherwise stated.to patients with chronic diseases such as asthma, hyper-
glycemia, and hypertension.
Montelukast sodium (MO), 1-[({(R)-m-[(E)-2-(7-chloro-
2-quinolyl)-vinyl]-α-[o-(1-hydroxy-1-methylethyl) phenethyl]-
benzyl}thio)methyl]cyclopropane acetate (Figure 1) is a
selective leukotriene receptor antagonist for uses similar
to those of zafirlukast, although it is reported to have a
longer duration of action [1]. Gliclazide (GL), N-(4-
methylbenzenesulfonyl)-N- (3-azabicyclo- [3.3.0] oct-3-)
urea (Figure 1) is a second-generation sulfonylurea [2].
Nifedipine (NI), dimethyl-1,4-dihydro-2,6-dimethyl-4-(2-
nitrophenyl)pyridine-3,5-dicarboxylate, is a calcium chan-
nel blocker that inhibits the trans-membrane influx oftral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public




Figure 1 Chemical structures of montelukast, gliclazid and
nifedipine.
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http://journal.chemistrycentral.com/content/8/1/17Ca2+ into cardiac muscle cells and vascular smooth
muscle through specific ion channels [3-5].
Several methods have been developed to quantitatively
estimate MO concentration, including voltammetry [6],
capillary electrophoresis [7], spectroflurometry [8], spectro-
photometry [9], and liquid chromatography (LC) [10-19].
Some of these methods were developed to monitor phar-
maceutical dosage forms [14-17] and drug concentrations
in biological fluids [8-13,18,19].
On the other hand, GL concentrations have been indi-
vidually determined using spectrophotometry [20-22],
radioimmunoassay [23], gas chromatography [24], HPLC
[25-28], and mass spectroscopy [29,30]. In addition, GL
concentrations have been determined in mixtures withmetformin [31-34], metformin and pioglitazone [35],
and rosiglitazone [36].
A detailed survey of the literature for NI revealed several
reported methods for the assay of NI either alone or in
combined drug formulations. These analytical techniques
include spectrophotometry [37-42], HPLC [43-47], high
performance thin layer chromatography [48], micellar
electrokinetic chromatography [49], electroanalytical
methods [50,51], flow injection analysis [52], and mass
spectrometry [53,54].
The present study aimed to develop a simple, sensitive,
reproducible, and rapid LC/MS/MS method to monitor
plasma levels of montelukast, gliclazide, and nifedipine




MO standard material (99.5% potency) and zaferolukast
(ZA) (I.S.) (99.3% potency) were kindly supplied by
Merck. GL and NI standard material (99.22% and 99.8%
potency, respectively) was kindly supplied by Sigma-
Aldrich Co. (UK). Singulair 10 mg tablets (MO) (Merk&Co.
Inc-USA), Diamicron 80 mg tablets (GL) (Servier), and
Epilat retard 20 mg tablets (NI) by EPICO, Egypt.
Formic acid was purchased from Romil chemicals,
England) and acetonitrile and methanol (HPLC grade)
were purchased from, Alpha Chemicals, Egypt). Deionized
water was obtained from a Milli-Q water purification sys-
tem 3 (Millipore, France), and human plasma was supplied
by VACSERA, Egypt). The mobile phase was filtered
through a 0.45-μm Whatman membrane filter.
Instruments and chromatographic conditions
An Agilent triple quadrupole mass spectrometer with an
API source coupled with an Agilent pump controlled by
an Agilent 1200 controller and equipped with an Agilent
1200 autosampler injector was used for analysis. Separ-
ation was performed using an analytical Agilent SB-C18
column (50 × 4.6 mm) with particle size of 1.8 μm. The
mobile phase consisting of acetonitrile: 0.1% formic acid
(84:16), was delivered at a flow rate of 0.6 mL/min.
Mass spectra were obtained using an electrospray
ionization source operated in the multiple reaction moni-
toring (MRM) mode. Sample introduction and ionization
were both performed in the positive ion mode (MO, GL,
and NI) and negative ion mode (ZA). The cone voltage
was set at 135 V for both MO and GL and 80 V and 150 V
for NI and ZA, respectively. The capillary voltage was op-
timized at 4000 V. Argon was used as the collision gas.
The collision energy was set at 20, 15, 5, and 25 MeV for
MO, GL, NI, and ZA, respectively. Optimal gas flow dur-
ing tuning was 8 L/min and nebulizer pressure was 30 psi.
The source temperature was 325°C. The selected mass
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315.2 at (positive ion) and 574.6/462.2 at (negative ion) for
MO, GL, NI, and ZA (I.S.), respectively. Agilent Mass
Hunter software was used for data acquisition. For
quantification, the peak area ratios of the target ions of
the drugs to those of the internal standard were com-
pared with weighted (1/concentration2) least square
calibration curves in which the peak area ratios of the cali-
bration standards were plotted versus their concentrations.Preparation of stock solutions and calibration standards
Stock solutions of each of the MO, GL, NI, and ZA (I.S.)
samples were prepared in methanol at a concentration
of 100.0 μg/mL and stored at 4°C. Handling and analysis
of all samples were performed under diffused light condi-
tions (prepared away from light using opaque glasses and
aluminum foil). Evaluations of the assay were performed
by seven point calibration curves made by serial dilutions
of the stock solution of each drug at the nominal concen-
tration ranges of 10.0–800.0 ng/mL, 10.0–5000.0 ng/mL,
and 10.0–600.0 ng/mL for MO, GL, and NI, respectively,
in human plasma. The slopes and intercepts of the calibra-
tion lines were determined.Sample preparation
Sample preparation was performed by liquid–liquid ex-
traction of 100 μL of plasma by protein precipitation using
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Figure 2 Mass spectra of the positive ion of montelukast (MO), gliclaz
internal standard.standard solution was added. The mixture was then
shaked by vortex for 30 s and centrifuged for 10 min at
4000 rpm. A 20 μL aliquot of the supernatant was injected
into the LC/MS/MS instrument.Clinical protocol
This method was applied for the analysis of plasma sam-
ples after the administration of a single dose of 10 mg
MO (Singulair tablets), 80 mg GL (Diamicron tablets),
and 20 mg NI (Epilat retard tablets) to six healthy male
volunteers. The study protocol was approved by the Ethics
Committee of Bioavailability Studies (NODCAR). The age
of the volunteers ranged from 29 to 39 years and the body
weights of the subjects ranged from 58 to 71 kg. All
subjects provided written informed consent. The study
was conducted in accordance with the provisions of the
Declaration of Helsinki. After an overnight fast for 10 h,
all volunteers received a single dose of the three drugs
with 200 mL of water. Blood samples (3 mL) from a
suitable antecubital vein were collected into heparin-
coated tubes at 0.0 (before dose), 0.25, 0.5, 0.75, 1.0, 1.5,
2.0, 2.5, 3, 4, 6.0, 8.0, 10.0, 12.0, 24.0, and 48.0 h post
dosing. The blood samples were centrifuged at 3000 rpm
for 5 min at room temperature and the plasma was re-
moved and stored at −80°C until assayed for MO, GL, and
NI content. All samples from a single volunteer were ana-
lyzed in the same run in order to avoid inter-assay
variations. 462.2) gmn pl5.d 
462.2 (ZA)
s-to-Charge (m/z)
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Figure 3 MRM chromatograms of blank plasma (A), gliclazide (B), nifedipine (C), zaferolukast (D) and montelukast (E).
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Pharmacokinetic parameters from the human plasma
samples were calculated by a noncompartmental model
using the WinNonlin 5.3 software. Blood samples were
taken for a period of 48 h. and it was considered as the
area under the concentration–time curve (AUC) ratios
were higher than 80% as per FDA guidelines [55,56]. The
first-order terminal elimination rate constant (Kel) was es-
timated by linear regression from the points describing
the elimination phase on a log-linear plot. The maximum
observed plasma concentration (Cmax) and the time taken
to achieve this maximum level (tmax) were directly ob-
tained from the curves.
The areas under the time-concentration curve for
MO, GL, and NI plasma concentration versus time for
48 h (AUC0–48) were calculated using the trapezoidalmethod. Extrapolation of this area to infinity (AUC0–∞)
was performed by adding the value C48/Kel to the calcu-
lated AUC0–48 where C48 is the MO, GL, and NI plasma
concentration at 48 h. Kel is the first-order terminal
elimination rate constant.
Results and discussion
New methods for simultaneous determination of two
or more compounds without interference from each
other are always of interest. The goal of this work
was to develop and validate a simple, rapid, and sen-
sitive LC/MS/MS assay method for simultaneous ex-
traction and quantification of montelukast, gliclazide,
and nifedipine in plasma and to apply this method
in a pharmacokinetic study. To achieve these goals,
during method development, different options were
Table 1 Intra-day and inter-days precision and accuracy for determination of montelukast in spiked human plasma
Theoretical concentration (ng/mL)
Parameters
Intra-day reproducibility Inter-days reproducibility
10 20 40 80 120 400 800 10 20 40 80 120 400 800
Concentration found (ng/mL)
Mean 10.93 19.9 38.5 77.43 109.16 372.45 808.55 10.37 18.92 37.95 78.23 105.58 392.03 816.69
Precision 1.69 7.79 4.49 8.73 4.56 14.13 7.68 13.74 12.52 14.01 13.81 11.34 14.14 12.84
Accuracy (%) 109.32 99.5 96.24 96.79 109.16 93.11 101.07 103.66 94.59 94.89 97.79 105.58 98.01 102.09
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parameters, and chromatography.
Method development
LC conditions were optimized to obtain a short run time
and adequate resolution between MO, GL, NI, and the
internal standard ZA. Several trials were performed to
select an optimal ratio of acetonitrile to 0.1% formic
acid. These trials determined that 86% acetonitrile ratio
was optimal for simultaneous separation of the three
drugs. Using this mobile phase delivered at a flow rate of
0.6 mL/min resulted in improved signals when com-
pared with different ratios of same reagents. In addition,
MS parameters were optimized to obtain maximum
sensitivity.
Electrospray ionization (ESI) was evaluated to obtain a
better response from the analytes. The best signal was
achieved using an ESI-positive ion mode for MO, GL,
and NI, and negative ion mode for ZA. The product ion
spectrum for MO, GL, NI, and ZA yielded a high abun-
dance of fragment ions of m/z 568.3, 127.2, 315.2, and
462.2, respectively (Figure 2). The representative extracted
ion chromatograms of the three drugs and the internal
standard are shown in Figure 3.
Method validation
Selectivity, linearity, limit of detection, and limit of
quantitation
The selectivity of the method was evaluated by comparing
the chromatograms obtained from the MO, GL, and NI
samples and the internal standard with those obtained
from the blank samples. A representative chromatogram




10 20 100 250 500 1000 50
Concentration fo
Mean 11.49 18.5 89.75 241.79 512.61 1045.04 476
Precision 7.35 11.1 13.49 11.42 5.33 0.6 10
Accuracy (%) 114.86 92.5 89.75 96.72 102.52 104.5 95chromatograms of the spiked plasma samples are shown
in Figure 3B, C, D, and E. Under the optimized conditions,
a linear relationship with a good correlation coefficient
(r = 0.999, n = 6) was observed between the peak area
ratios and the concentrations of MO, GL, and NI in the
range of 10.0–800.0, 10.0–5000.0, and 10.0–600.0 ng/mL,
respectively. The experiments were performed using a
standard seven-point series for each drug.
The limit of detection (LOD) and limit of quantitation
(LOQ) were calculated according to the ICH guidelines
for validation of analytical procedures based on the stand-
ard deviation of the response and the slope of the calibra-
tion curve [57] using the formula: LOD or LOQ= κσ/S,
where κ = 3.3 for LOD and 10 for LOQ, σ is the standard
deviation of the response, and S is the slope of the calibra-
tion curve. Calculations of six replicate experimental injec-
tions determined LODs of 0.04, 0.01, and 0.02 ng/mL and
LOQs of 0.11, 0.04, and 0.07 ng/mL for MO, GL, and NI,
respectively.
Accuracy and precision
The accuracy and precision of the proposed method
were determined by intra-day and inter-day replicate
analyses of plasma spiked with different concentrations
of each drug covering the working linear ranges. The
inter-day assays were carried out on three different
days with the same concentration levels for spiked
plasma samples. The accuracy values from the intra-
day analysis were 94.59% –105.58%, 89.75% −114.86%,
and 83.46%–110.22%, whereas the values for the inter-
day analysis were 93.11%, −109.32%, 99.93%–106.16%,
and 97.90%–114.82% for MO (Table 1), GL (Table 2),
and NI (Table 3), respectively, indicating the accuracy andetermination of gliclazide in spiked human plasma
l concentration (ng/mL)
Inter-days reproducibility
00 10 20 100 250 500 1000 5000
und (ng/mL)
7.74 10.27 19.99 106.16 261.21 527.12 1037.07 5215.71
.92 15.54 15.17 15.39 14.92 4.17 3.22 10.49
.35 102.68 99.93 106.16 104.48 105.42 103.71 104.31
Table 3 Intra-day and inter-days precision and accuracy for determination of nifedipine in spiked human plasma
Theoretical concentration (ng/mL)
Parameters
Intra-day reproducibility Inter-days reproducibility
10 20 40 80 100 200 600 10 20 40 80 100 200 600
Concentration found (ng/mL)
Mean 8.35 21.33 44.09 83.93 101.1 203.63 634.48 10.51 20.01 39.16 91.17 114.82 227.41 664.38
Precision 4.21 10.55 6.69 8.09 4.2 2.76 1.45 8.84 5.7 15.54 14.52 4.86 1.82 2.47
Accuracy (%) 83.46 106.67 110.22 104.91 101.1 101.82 105.75 105.08 100.04 97.9 113.96 114.82 113.7 110.73
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that had greater concentrations compared with the highest
concentration in the validation were diluted before in-
jection and the actual concentrations were recalculated.
Application to pharmacokinetic study
The method described here was successfully applied to
a pharmacokinetic study of MO, GL, and NI in plasmaFigure 4 MRM chromatogram of Gliclazide (GL), Nifedipine (NI), zafer
of healthy volunteer (Subject No. 2, at 6 h.).samples from healthy human volunteers. None of the
volunteers exhibited any general adverse reactions. Fol-
lowing oral drug administration, plasma concentration–
time profiles of the three drugs best fit a non-
compartment in all subjects. A representative MRM
chromatogram of a plasma sample extracted from a
healthy volunteer at 6 h is shown in Figure 4. A repre-
sentative plasma concentration–time profile is shown inolukast (ZA), and Motelukast (MO) extracted from plasma sample
Figure 5 Mean (±SD) Plasma Concentration versus time of montelukast (A), gliclazide (B) and nifedipine (C) following simultaneous
administration of montelukast (10 mg), gliclazide (80 mg) and nifedipine (20 mg) Tablets to six healthy male volunteers.
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are shown in Table 4.
Conclusions
The results of this study showed that the validated
LC/MS/MS method proved to be a simple, rapid,Table 4 Pharmacokinetic Parameters required for assessment
Parameters Montelukast
Cmax (ng/mL) 882.39 ± 245.8
AUC 0–48 (ng.h/mL) 4493.23 ± 2576.3
AUC 0-α (ng.h/ml) 4797.49 ± 2808.6
tmax (median) h 4.25
t1/2 (h) 3.86 ± 27
MRT (h) 7.27 ± 3.7
Kel (h) 0.282 ± 0.32reliable, selective, and sensitive method sufficient for
simultaneous monitoring of pharmacokinetic parame-
ters of montelukast, gliclazide, and nifedipine. A small
plasma sample volume and LOQ were sufficiently sen-
sitive to detect terminal phase concentrations of the
drugs.of Montelukast, Gliclazide and Nifedipine Bioavailability
Gliclazide Nifedipine
2917.2 ± 991.3 353.519 ± 104.5
45156.15 ± 45988.13 1261.81 ± 155.1
49915.8 ± 51881.3 1423.3 ± 295.5
8.00 4.24
7.24 ± 8.3 2.7 ± 0.36
15.46 ± 11.6 5.88 ± 3.1
0.240 ± 0.17 0.255 ± 0.03
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Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
EE proposed the subject, designed the study, conducted pharmacokinetic
and statistical analysis, participated in the results discussion and revised
manuscript. NFA participated in study design, assay design, literature review,
conducted the validation of the assay, analysis of the samples, participated in
the results discussion and participated in preparing the manuscript. MHT
participated in study design, assay design, literature review, conducted the
validation of the assay, analysis of the samples, participated in the results
discussion and participated in preparing the manuscript. AAA participated in
the writing the manuscript. All authors read and approved the final
manuscript
Acknowledgment
The authors extend their appreciation to the Deanship of Scientific Research
at King Saud University for funding the work through the research group
project No. RGP-VPP-262.
Author details
1Drug Bioavailability Lab.College of Pharmacy, King Saud University, P.O. Box
2457, Riyadh 11451, Saudi Arabia. 2Drug Bioavailability Center, National
Organization for Drug Control and Research, P.O.Box 29, Cairo, Egypt.
3Department of Pharmacognosy, College of Pharmacy, King Saud University,
P.O. Box 2457, Riyadh 11451, Saudi Arabia.
Received: 27 October 2013 Accepted: 4 March 2014
Published: 11 March 2014
References
1. García-Marcos L, Schuster A, Pérez-Yarza EG: Benefit-risk assessment of
antileukotrienes in the management of asthma. Drug Saf 2003,
26:483–518.
2. Palmer KJ, Brogden N: Gliclazide an update of its pharmacological
properties and therapeutic efficacy in non-insulin-dependent diabetes
mellitus. Drugs 1993, 46:92–125.
3. Miller RJ: Multiple calcium channels and neuronal function. Science 1987,
235:46–52.
4. Murdoch D, Brogden RN: Sustained release nifedipine formulations: an
appraisal of their current uses and prospective roles in the treatment of
hypertension, ischaemic heart disease and peripheral vascular disorders.
Drugs 1993, 41:737–779.
5. Weetman SC: Martindale The Extra Pharmacopoeia. 33rd edition. London:
Royal Pharmaceutical Society; 2002:940–946.
6. Alsarra I, Al-Omar M, Gadkariem EA, Belal F: Voltammetric determination of
montelukast sodium in dosage forms and human plasma. Farmaco 2005,
60:563–567.
7. Shakalisava Y, Regan F: Determination of montelukast sodium by capillary
electrophoresis. J Sep Sci 2008, 31:1137–1143.
8. Alsarra I, Khalil NY, Sultan M, Al-Ashban R, Belal F: Spectrofluorometric
determination of montelukast in dosage forms and spiked human
plasma. Pharmazie 2005, 60:823–826.
9. Saeed Arayne M, Sultana N, Hussain F: Spectrophotometric method for
quantitative determination of montelukast in bulk, pharmaceutical
formulations and human serum. J Anal Chem 2009, 64:690–695.
10. Bharathi DV, Hotha KK, Jagadeesh B, Mullangi R, Naidu A: Quantification of
montelukast, selective cysteinyl leukotriene receptor (CysLT1) antagonist
In human plasma by liquid chromatography- mass spectrometry-
validation and its application to a human pharmacokinetic study.
Biomed Chromatogr 2009, 23:804–810.
11. Sripalakit P, Kongthong B, Saraphanchotiwitthaya A: A simple bioanalytical
assay for determination of montelukast in human plasma- application to
a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci
2008, 869:38–44.12. Smith GA, Rawls CM, Kunka RL: An automated method for the
determination of montelukast in human plasma using dual-column
HPLC analysis and peak height summation of the parent compound and
its photo degradation product. Pharm Res 2004, 21:1539–1544.
13. Papp R, Luk P, Mullett WM, Kwong E: A rapid and sensitive method for
the quantitation of montelukast in sheep plasma using liquid
chromatography/tandem mass spectrometry. J Chromatogr B Analyt
Technol Biomed Life Sci 2007, 858:282–286.
14. Saravanan M, Siva Kumari K, Pratap Reddy P, Naidu MN, Moses Babu J,
Srivastava AK, Lakshmi Kumar T, Chandra Sekhar BV, Satyanarayana B:
Identification, synthesis, isolation and spectral characterization of potential
impurities of montelukast sodium. J Pharm Biomed Anal 2008, 48:708–715.
15. Al Omari MM, Zoubi RM, Hasan EI, Khader TZ, Badwan AA: Effect of light
and heat on the stability of montelukast in solution and in its solid state.
J Pharm Biomed Anal 2007, 45:465–471.
16. Hoang TH, Sharma R, Susanto D, Di Maso M, Kwong E: Microwave-assisted
extraction of active pharmaceutical ingredient from solid dosage forms.
J Chromatogr A 2007, 1156:149–153.
17. Prashanth Kumar K, Akiful Haque M, Pradeep Kumar T, Nivedita G, Hasan
Amrohi S, Prasad VV, Prakash VD: Simultaneous determination of
Montelukast sodium and fexofenadine hydrochloride in combined
dosage form by using RP-HPLC method. World J Chem 2012, 7(2):42–46.
18. Balasekhara RC, Bahlul ZA, Babu RC, Mukkanti K, Chandrasekhar BK: Method
development and validation of Montelukast in human plasma by HPLC
coupled with ESI-MS/MS: application to a bioequivalence study.
Sci Pharm 2010, 78:411–422.
19. Alireza S, Afshin Z, Seyed MF, Arash K, Babak M: Rapid and sensitive
determination of Montelukast in human plasma by high performance
liquid chromatographic method using monolithic column: application to
pharmacokinetic studies. J Bioequiv Availab 2010, 2:135–138.
20. Revathi R, Saravanan VS, Mohan Raj P, Ethiraj T, Ganesan V:
Spectrophotometric Estimination of Gliclazide in Bulk and
Pharmaceutical Dosage Forms. Int Res J Pharm 2010, 1:277–281.
21. Samina AJ, Snehal PM, Poonam SK, Yogesh VP, Kishor BB: Development
and validation of UV spectrophotometric method for the determination
of Gliclazide in tablet dosage form. Der Pharma Chemica 2011, 3:338–343.
22. Pinderjit S, Rajnish K, Harinder S: Application of UV spectrophotometric
method for analysis of gliclazide in pharmaceutical dosage forms. Int J
Pharm Pharm Sci 2011, 3:259–260.
23. Suzuki H, Miki M, Sekine Y, Kagemoto A, Negoro T, Maeda T, Hashimoto M:
Determination of new hypoglycaemic drug Gliclazide in human serum
by radio immunoassay. J Pharmacobiodyn, 4(3):217–225.
24. Maeda T, Yamaguchi T, Hashimoto M: Gas chromatographic
determination of the hypoglycaemic agent gliclazide in plasma.
J Chromatogr B Biomed Sci Appl 1981, 223:357–363.
25. Kuo CY, Wu SM: High-performance liquid chromatography with
electrochemical detection for analysis of gliclazide in plasma. J
Chromatogr A 2005, 1088:131–135.
26. Damanjeet G, Lakshmi GG: HPLC method for determination of Gliclazide
in human serum. Asian j Chem 2009, 21:4258–4264.
27. Park JY, Kim KA, Kim SL, Park PW: Quantification of gliclazide by semi-micro
high-performance liquid chromatography: application to a bioequivalence
study of two formulations in healthy subjects. J Pharm Biomed Anal 2004,
35:943–949.
28. Jia-Feng Y: Determination of Gliclazide in human plasma by high
performance liquid chromatography. Asian J Drug Metab Pharmacokinet
2004, 4:231–234.
29. Maurer HH, Kratzsch C, Kraemer T, Peters FT, Weber AA: Screening, library-
assisted identification and validated quantification of oral antidiabetics
of the sulfonylurea-type in plasma by atmospheric pressure chemical
ionization liquid chromatography-mass spectrometry. J Chromatogr B
Anal Technol Biomed Life Sci 2002, 773:63–73.
30. Wang CY, Zhang W, Xiang BR, Yu LY, Ma PC: Liquid chromatography -
mass spectrometry method for the determination of gliclazide in human
plasma and application to a pharmacokinetic study of gliclazide
sustained release tablets. Arzneimittelforschung 2008, 58(12):653–658.
31. Ediga V, Krishna R, Chandra KS: A new simple RP-HPLC method for
simultaneous estimation of Metformin Hcl and Gliclazide tablet dosage
form. Int J Pharm Bio Sci 2012, 4:277–283.
32. Kanij F, Md Zakir R, Tasnuva H, Mohammad Abul Kalam A, Md Selim R:
Development and validation of a simple method for simultaneous
Ezzeldin et al. Chemistry Central Journal 2014, 8:17 Page 9 of 9
http://journal.chemistrycentral.com/content/8/1/17estimation of Metformin hydrochloride and gliclazide in tablets by using
RP-HPLC. Dhaka Univ J. Pharm Sci 2010, 9:83–89.
33. Dhabale PN, Seervi CR: Simultaneous UV spectrophotometric method for
estimation of gliclazide and metformine hydrochloride in tablet dosage
form. Int J Chem Tech Res 2010, 2:813–817.
34. Ketan PD, Parthika AN, Yadvendra KA: Development and validation of
spectrophotometric method for simultaneous estimation of gliclazide
and metformin hydrochloride in bulk and tablet dosage form by
simultaneous equation method. Int J Pharm Sci Res 2011, 2:1559–1563.
35. Nazar Mustafa M, Anurekha J: Simultaneous estimation of metformin
hydrochloride, pioglitazone hydrochloride and gliclazide by validated
rp-hplc method in solid dosage form. Int J Pharm Pharm Sci 2012, 4:72–76.
36. Rathinavel G, Umanath U, JValaramathy J, Samuel Joshua L, Selvin Thanuja
C, Ganesh M, Shivkumar T, Priyadarsini R: RP-HPLC method for
simultaneous estimation of rosiglitazone and gliclazide in tablets.
E J chem 2009, 6(4):1188–1192.
37. Kasture AV, Ramteke M: Simultaneous UV-Spectrophotometric methods
for the estimation of Atenolol and Nifedipine in solid dosage forms.
Ind J Pharm Sci 2005, 67:752–754.
38. Hemmateenejada B, Miri R, Kamali R: A Kinetic spectrophotometric
method for determination of amlodipine and Nifedipine in
pharmaceutical preparations. J Iran Chem Soc 2009, 6:113–120.
39. Rahman N, Najmul S, Azmi H: New spectrophotometric methods for the
determination of nifedipine in pharmaceutical formulations. Acta Biochim
Pol 2005, 52:915–922.
40. Sastry CSP, Chintalapati R, Venkateswarlu R: A simple spectrophotometric
method for estimation of nifedipine. J Inst Chem 1997, 69:187.
41. Revathi R, Ethiraj T, Saravanan VS, Ganeshan V, Saranya V, Sengottuvel T:
New spectrophotometric determination of nifedipine using hydrotropic
solubilization. Int J Pharm Pharm Sci 2010, 2:74–76.
42. Segun AA, Olajire AA, Olakunle SI: A new colorimetric method for
thedetermination of nifedipine tablets by derivatization using 4-carboxyl
2,6dinitrobenzene diazonium ion. Int J Ind Chem 2012, 3:1–8.
43. Yritia M, Parra P, Igelisias E, Barbanoj JM: Quantitation of nifedipine
inhuman plasma by on-line solid-phase extraction and high-
performanceliquid chromatography. J Chromatog A 2000, 870:115–119.
44. Zendelovska D, Simeska S, Sibinovska O, Kostova E, Milosevska K, Jakovski K,
Jovanovska E, Kikerkov I, Trojacanec J, Zafirov D: Development of an HPLC
method for the determination of nifedipine in human plasma by
solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci 2006,
24(839):85–88.
45. Awad Uday Y, Shravan Kumar P, Dinesh Kumar A, Bari S: Estimation of
nifedipine by reverse phase high performance liquid chromatography
tablet dosage form. Int. J. of Pharm. & Life Sci 2011, 2:610–612.
46. Ahmad M, Ahmad T, Sultan RA, Murtaza G: Pharmacokinetic Study
ofNifedipine in Healthy Adult Male Human Volunteers. Trop J Pharm Res
2009, 8(5):385–391.
47. Mahmood A, Tasneem A, Rafi AS, Jamal K, Ghulam M: Bioavailability
andpharamcotherapeutics of nifedipine in human after single oral dose
administration. Acta Pharmaceutica Sciencia 2010, 52:45–54.
48. Patravale VB, Nair VB, Gore SP: High performance thin layer
chromatographic determination of nifedipine from bulk drug and from
pharmaceuticals. J Pharm Biomed Anal 2000, 23:623–627.
49. Bretnall AE, Clarke GS: Investigation and optimisation of the use of
micellar electrokinetic chromatography for the analysis of six
cardiovascular drugs. J Chromatogr A 1995, 700:173–178.
50. Dumitrescu V, David V, Pavel A: Polarographic determination of nifedipine
and chloramphinicol. Rev Chim 2001, 52:317–320.
51. Ghoneim MM, Tawfik A, Khashaba PY: Cathodic adsorptive stripping
square-wave voltammertic detetermination of nifedipine drug in bulk,
pharmaceutical formulation and human serum. Anal Bioanal Chem 2003,
375:369–375.
52. Richter P, Toral MI, Quiroz G, Jaque P: Flow-through polarographic cell for
flow-injection analysis determination of nifedipine in pharmaceutical
formulations. Lab Rob Autom 1997, 9:255–262.
53. Streel B, Zimmer C, Sibernaler R, Ceccato A: Simultaneous determination
of nifedipine and dehydronifedipine in human plasma by liquid
chromatography-tandem mass spectrometry. J Chromatogr B Biomed Sci
Appl 1998, 720:119–128.
54. Srinivas R, Iqbal A, Nirmala N, Saral T, Arindam M: Estimation of nifedipine
in human plasma by LC/MS/MS. Asian J Pharm Clin Res 2013, 6:83–86.55. Food and Drug Administration (FDA): Guidance for Industry Food- Effect bio
Availability and Fed Bio Equivalence Studies. USA: U.S. Department of Health
and Human services Food and Drug Administration Centre for Drug
Evaluation and research (CDER); 2002.
56. Food and Drug Administration (FDA): Guidance for Industry Bio Availability
and Fed Bio Equivalence Studies for Orally Administered Drug Products-General
Considerations. USA: U.S. Department of Health and Human services Food
and Drug Administration Centre for Drug Evaluation and research (CDER);
2003.
57. ICH Guideline, Q2(R1): Validation of Analytical Procedure. London: Text and
Methodology London; 2005.
doi:10.1186/1752-153X-8-17
Cite this article as: Ezzeldin et al.: Development and validation of LC/
MS/MS method for the simultaneous determination of montelukast,
gliclazide, and nifedipine and its application to a pharmacokinetic
study. Chemistry Central Journal 2014 8:17.Open access provides opportunities to our 
colleagues in other parts of the globe, by allowing 
anyone to view the content free of charge.
Publish with ChemistryCentral and every
scientist can read your work free of charge
W. Jeffery Hurst, The Hershey Company.
available free of charge to the entire scientific community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central
yours     you keep the copyright
Submit your manuscript here:
http://www.chemistrycentral.com/manuscript/
